8-K filing — Ocugen, Inc. (OCGN)
Filed: 2026-10-15 AccNo: 0001104659-26-115970 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Ocugen Receives Bahamas Regulator Provisional Approval For OCU400 Has Been Granted Approval And Priority Designation; The Company Will Supply OCU400 Through An EAP, With Goal Of Treating First RP Patient Within 90 Days
Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ocugen shares are trading lower. The company announced a licensing agreement with Roots Pharmaceutical for exclusive MENA rights to OCU400, its gene therapy for Retinitis Pigmentosa.
Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region
Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access to a potential
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.